Susquehanna International Group
VKTXW

Susquehanna International Group’s Viking Therapeutics, Inc. VKTXW Stock Holding History

Susquehanna International Group’s Portfolio VKTXW Stock Details VKTXW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,625
Closed -$62K – 11439
2020
Q2 		$62K Sell
10,625
-3,503
-25% -$18.5K ﹤0.01% 9695
2020
Q1 		$43K Sell
14,128
-7,280
-34% -$33.2K ﹤0.01% 9740
2019
Q4 		$139K Sell
21,408
-12,404
-37% -$72.6K ﹤0.01% 8987
2019
Q3 		$181K Buy
33,812
+12,459
+58% +$73.4K ﹤0.01% 9192
2019
Q2 		$144K Buy
+21,353
New +$153K ﹤0.01% 9401
2018
Q2 		– Sell
-14,012
Closed -$43K – 10750
2018
Q1 		$43K Sell
14,012
-132,588
-90% -$542K ﹤0.01% 9001
2017
Q4 		$371K Sell
146,600
-133,500
-48% -$233K ﹤0.01% 7201
2017
Q3 		$204K Sell
280,100
-3,500
-1% -$1.5K ﹤0.01% 7991
2017
Q2 		$71K Sell
283,600
-3,100
-1% -$1.24K ﹤0.01% 8815
2017
Q1 		$143K Sell
286,700
-16,000
-5% -$6.7K ﹤0.01% 8231
2016
Q4 		$136K Buy
+302,700
New +$129K ﹤0.01% 8917

Other funds holding VKTXW

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Susquehanna International Group's VKTXW Position: Q3 2020 in Review

Susquehanna International Group sold out of Viking Therapeutics, Inc. (VKTXW) in Q3 2020, closing a stake of 10,625 shares — an estimated $62K sold.

Susquehanna International Group first reported a position in VKTXW in Q4 2016 and held it in 11 quarters. The position peaked at $371K in Q4 2017. 2 funds tracked by Wall St. Rank hold VKTXW as of Q3 2020.

  • Susquehanna International Group reported no remaining Viking Therapeutics, Inc. position as of Q3 2020 after selling out during the quarter.
  • Susquehanna International Group sold 10,625 Viking Therapeutics, Inc. shares in Q3 2020, an estimated $62K.
  • Susquehanna International Group first reported a position in Viking Therapeutics, Inc. in Q4 2016 and held it in 11 quarters.
  • Susquehanna International Group's Viking Therapeutics, Inc. position peaked at $371K in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Viking Therapeutics, Inc. as of Q3 2020.

Based on Susquehanna International Group's 13F filing for Q3 2020, filed 16 Nov 2020.